NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Pemetrexed for the treatment of non-small cell lung cancer

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Eli Lilly and Company Ltd	British National Formulary
	NHS Quality Improvement Scotland
Patient/carer groups	
 Cancerbackup 	Possible comparator manufacturers
 Roy Castle Lung Cancer Foundation 	Roche Products Ltd
 Tenovus Cancer Information Centre 	Sanofi-Aventis
 Professional groups British Thoracic Society Cancer Networks Pharmacists Forum Cancer Research UK Royal College of Nursing Royal College of Pathologists Royal College of Physicians (Medical Oncology Joint Special Committee) Others Department of Health Welsh Assembly Government 	 Relevant research groups British Thoracic Oncology Group MRC CTU - Lung Cancer and Mesothelioma Group Evidence Review team Liverpool Reviews and Implementation Group, University of Liverpool National Coordinating Centre for Health Technology Assessment Associated Guideline Groups National Collaborating Centre for Cancer

National Institute for Health and Clinical Excellence Appraisal of pemetrexed for the treatment of non-small cell lung cancer

Issue date: November 2006

Definitions:

Manufacturer/Sponsor Consultee

The manufacturer/sponsor of the technology being appraised who make an evidence submission, comment on consultations and appeal against the Final Appraisal Determination (FAD).

Non-manufacturer/sponsor Consultees

The non-manufacturer consultee can comment on consultations, nominate experts and appeal against the Final Appraisal Determination (FAD).

Commentators

The commentator can comment on consultations, nominate experts and do not have the right to appeal against the Final Appraisal Determination (FAD).